Akston Biosciences Corporation (AXTN)

Akston Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2024	Dec 31, 2023
Revenue	6.97	16.49	5.11
Revenue Growth (YoY)	-	222.32%	-
Cost of Revenue	-	13.45	1.87
Gross Profit	0.23	3.04	3.25
Selling, General & Admin	-	11.3	7.17
Research & Development	-	6.58	5.16
Operating Expenses	-	17.88	12.33
Operating Income	-18.36	-14.84	-9.08
Interest Expense / Income	1.75	2.2	-0.1
Other Expense / Income	-21.61	-20.96	0.56
Pretax Income	1.5	3.91	-9.55
Income Tax	0.11	0.11	-
Net Income	1.39	3.81	-9.55
Free Cash Flow	-16.03	-13.66	-5.15
Gross Margin	3.34%	18.44%	63.53%
Operating Margin	-263.53%	-90.04%	-177.58%
Profit Margin	20.02%	23.10%	-186.66%
Free Cash Flow Margin	-229.98%	-82.85%	-100.62%
Effective Tax Rate	7.00%	2.68%	-
EBITDA	4.98	7.94	-8.04
EBITDA Margin	71.53%	48.14%	-157.22%
Depreciation & Amortization	1.73	1.82	1.6
EBIT	3.25	6.11	-9.65
EBIT Margin	46.65%	37.08%	-188.60%

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).